Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Sonic hedgehog subtype of medulloblastoma (SHH MB) with specific clinical or molecular alterations has a dismal prognosis, often leading to severe cognitive impairment in survivors. New targeted therapeutic approaches are urgently needed to improve treatment outcomes for children with SHH MB. The existing treatment, involving surgical resection, craniospinal radiation, and multi-agent chemotherapy, provides a 5-year survival rate of over 70% for newly diagnosed patients. However, this approach comes with significant side effects, including skeletal growth retardation, endocrine problems, psychiatric and social challenges, and progressive cognitive decline. SHH MB patients with specific characteristics, such as metastasis, post-operative residual disease, large-cell anaplastic histology, or MYCN amplification, continue to face a high to very high risk.

·       Medulloblastoma, the most common malignant brain tumor in children, primarily affects the cerebellum and is prevalent in approximately 1 in 150,000 children, with the highest incidence at five years of age.

Thelansis’s “Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Sonic Hedgehog Subtype of Medulloblastoma (SHH MB), Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) market outlook, Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) competitive landscape, Sonic Hedgehog Subtype of Medulloblastoma (SHH MB) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)